Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.63 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205511 | 0.85 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL1243900 | 0.85 | ELANE (0.79) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| Bay-678 SCHEMBL1245235 | 0.77 | ELANE (1.00) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| Bay-678 SCHEMBL1245297 | 0.77 | ELANE (1.00) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| Bay-677 SCHEMBL4179543 | 0.77 | ELANE (1.00) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| SCHEMBL1245423 | 0.77 | ELANE (0.87) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| SCHEMBL5202330 | 0.77 | ELANE (0.64) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| SCHEMBL1245171 | 0.76 | ELANE (0.85) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| SCHEMBL12890398 | 0.76 | ELANE (0.74) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| SCHEMBL8347439 | 0.76 | ELANE (0.59) | ELANECYP3A4CYP2C9ADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554246-B1 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060100207-A1 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100207-A1 | Dihydropyridinone derivatives | TNNI3, DHPS, TNNT2 | ELANE 260/4885CYP3A4 3343/4885CYP2C9 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.